DE69512930D1 - Stilben-derivate verwendbar als cyclooxygenase-2 hemmer - Google Patents

Stilben-derivate verwendbar als cyclooxygenase-2 hemmer

Info

Publication number
DE69512930D1
DE69512930D1 DE69512930T DE69512930T DE69512930D1 DE 69512930 D1 DE69512930 D1 DE 69512930D1 DE 69512930 T DE69512930 T DE 69512930T DE 69512930 T DE69512930 T DE 69512930T DE 69512930 D1 DE69512930 D1 DE 69512930D1
Authority
DE
Germany
Prior art keywords
cyclooxygenase
pct
stilb
inhibitors
derivatives used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69512930T
Other languages
English (en)
Other versions
DE69512930T2 (de
Inventor
Joseph Atkinson
Zhaoyin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of DE69512930D1 publication Critical patent/DE69512930D1/de
Application granted granted Critical
Publication of DE69512930T2 publication Critical patent/DE69512930T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/36—Amides thereof
DE69512930T 1994-10-27 1995-10-24 Stilben-derivate verwendbar als cyclooxygenase-2 hemmer Expired - Fee Related DE69512930T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33017294A 1994-10-27 1994-10-27
PCT/CA1995/000601 WO1996013483A1 (en) 1994-10-27 1995-10-24 Stilbene derivatives useful as cyclooxygenase-2 inhibitors

Publications (2)

Publication Number Publication Date
DE69512930D1 true DE69512930D1 (de) 1999-11-25
DE69512930T2 DE69512930T2 (de) 2000-05-18

Family

ID=23288609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512930T Expired - Fee Related DE69512930T2 (de) 1994-10-27 1995-10-24 Stilben-derivate verwendbar als cyclooxygenase-2 hemmer

Country Status (9)

Country Link
US (1) US5849943A (de)
EP (1) EP0788476B1 (de)
JP (1) JPH10507765A (de)
AT (1) ATE185797T1 (de)
AU (1) AU688980B2 (de)
CA (1) CA2200462A1 (de)
DE (1) DE69512930T2 (de)
ES (1) ES2139959T3 (de)
WO (1) WO1996013483A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
EP0904269B1 (de) * 1995-10-30 2002-01-23 Merck Frosst Canada & Co. 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
FR2754256B1 (fr) * 1996-10-08 1998-12-24 Union Pharma Scient Appl Nouveaux derives 1,2-diarylmethylenes, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2771005B1 (fr) * 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
ES2236007T3 (es) 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
MXPA02006312A (es) 1999-12-23 2004-06-21 Nitromed Inc Inhibidores de ciclooxigenasa-2 nitrosilatados y nitrosados, composiciones y metodos para utilizarse.
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CN102533972B (zh) 2002-05-09 2014-07-02 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的1l1rl-1
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
EP1539679A4 (de) * 2002-06-28 2007-07-04 Nitromed Inc Oxim- und/oder hydrazonhaltige, nitrosierte und/oder nitrosylierte cyclooxigenase-2-selektive inhibitoren, zusammensetzungen und anwendungsverfahren
AU2003252515A1 (en) 2002-07-26 2004-02-16 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US6960611B2 (en) 2002-09-16 2005-11-01 Institute Of Materia Medica Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof
US7169809B2 (en) 2003-03-05 2007-01-30 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
PL2384753T3 (pl) 2003-08-29 2016-09-30 Pochodne hydantoiny jako inhibitory martwicy komórkowej
EP2306192B1 (de) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risikomarker für eine Herzkreislaufkrankheit
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006044230A1 (en) * 2004-10-12 2006-04-27 Merck & Co., Inc. Water soluble prodrugs of cox-2 inhibitors
EP1814838A4 (de) * 2004-11-16 2010-03-17 Merck Sharp & Dohme Prodrugs aus (2r)-2-propyloctansäure zur behandlung von apoplexie
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
EP2924440A3 (de) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Mit arteriovaskulären ereignissen assoziierte marker und verfahren zur verwendung davon
EP2891885A3 (de) 2007-04-18 2015-10-14 Health Diagnostic Laboratory, Inc. Diabetesassoziierte Biomarker und Verfahren zu deren Verwendung
WO2008140251A2 (en) * 2007-05-14 2008-11-20 University-Industry Cooperation Group Of Kyung Hee University Cyclooxygenase-2 inhibitors
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2531163A1 (de) 2010-02-01 2012-12-12 The Hospital For Sick Children Ischämische remote-konditionierung zur behandlung und prävention von restenosen
KR20130040851A (ko) 2010-03-31 2013-04-24 더 호스피탈 포 식 칠드런 심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
CN107674071B (zh) 2012-05-11 2021-12-31 同步制药公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CA3113353A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3852732A1 (de) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg-lipide und deren verwendung
KR20210124188A (ko) * 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012786A1 (fr) * 1989-04-24 1990-11-01 Otsuka Pharmaceutical Factory, Inc. Derive de 3-halogeno-2,3-diphenylacrylaldehyde, son procede de fabrication et agent de traitement de l'hyperlipidemie
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation

Also Published As

Publication number Publication date
ES2139959T3 (es) 2000-02-16
EP0788476A1 (de) 1997-08-13
US5849943A (en) 1998-12-15
CA2200462A1 (en) 1996-05-09
ATE185797T1 (de) 1999-11-15
AU3695095A (en) 1996-05-23
AU688980B2 (en) 1998-03-19
JPH10507765A (ja) 1998-07-28
DE69512930T2 (de) 2000-05-18
EP0788476B1 (de) 1999-10-20
WO1996013483A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
DE69512930D1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
FI971967A (fi) Dioksomorfoliinien käyttö sisäloisten torjuntaan, uusia dioksomorfiineja ja menetelmä niiden valmistamiseksi
NL300175I2 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
ATE196765T1 (de) Dihydrobenzofurane
ATE212343T1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69410092T2 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
MX9203053A (es) Derivados de aza nor bornano.
ID22042A (id) Benzonaftiridin sebagai pengobatan cabang tenggorokan
DE69516503T2 (de) Piperidinderivate mit paf antagonistischer wirkung
ES2143666T3 (es) P-amidinobencilamidas dipeptidicas con restos sulfonilo, o bien aminosulfonilo n-terminales.
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
ATE223376T1 (de) Bisarylcyclobutenderivate als cyclooxygenasehemmer
PT775143E (pt) Novos derivados de 3h-2,3-benzodiazepina 3-substituidos sua preparacao e utilizacao
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.
DE69623767T2 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
IT1275436B (it) Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza
SE9401596D0 (sv) New compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK FROSST COMPANY, HALIFAX, NOVA SCOTIA, CA

8339 Ceased/non-payment of the annual fee